[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349132-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-349132-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","correlation-between-recognition-of-autologous-tumor-organoids-by-tumor-infiltrating-lymphocytes-from-metastatic-epithelial-cancers-and-clinical-response","Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response","","Neoantigen-specific tumor-infiltrating lymphocytes (TILs) can mediate clinical responses in patients with metastatic epithelial cancers, yet reliable predictors for adoptive cell therapy remain limited. Patient-derived tumor organoids (PDTO) preserve tumor genetic features and provide a personalized platform to test anticancer effectiveness. Tumor organoids were generated from patients receiving a TIL protocol, and TIL recognition and RECIST objective responses were measured.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/correlation-between-recognition-of-autologous-tumor-organoids-by-tumor-infiltrating-lymphocytes-from-metastatic-epithelial-cancers-and-clinical-response/349132/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/correlation-between-recognition-of-autologous-tumor-organoids-by-tumor-infiltrating-lymphocytes-from-metastatic-epithelial-cancers-and-clinical-response/349132.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study aiming to predict for TIL adoptive cell therapy?","Question",{"text":63,"@type":64},"The study aimed to determine which patients with metastatic epithelial cancers would benefit from adoptive cell therapy with TIL by assessing recognition of autologous tumor organoids.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were tumor organoids (PDTO) and TIL recognition measured?",{"text":68,"@type":64},"Tumor organoids were grown from patients on a TIL protocol. TIL recognition of autologous PDTO was measured using enzyme-linked immunosorbent spot assays and 4-1BB upregulation, alongside RECIST objective response assessment.",{"name":70,"@type":61,"acceptedAnswer":71},"Did lack of initial PDTO recognition relate to clinical response?",{"text":72,"@type":64},"Yes. There were no responders among 9 patients who lacked PDTO recognition on initial TIL screening, compared with 7 responses in 18 patients with initial reactivity.",{"name":74,"@type":61,"acceptedAnswer":75},"What did the study conclude about autologous tumor organoid recognition?",{"text":76,"@type":64},"TIL reactivity against autologous tumor organoids was associated with higher likelihood of objective clinical response in patients with metastatic epithelial cancers.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},349132,1790153143,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \n Correlation between recognition of  \nautologous tumor organoids by tumorinfiltrating lymphocytes from metastatic epithelial cancers and clinical response  \nAlexandra M Gustafson,1,2 Aarushi Bhasin,1 Billel Gasmi,1,3 Brian D Bui  ,1 Catherine Marie Ade  ,1 Ken-ichi Hanada,1 Hyunmi K Halas,1 Jared J Gartner,1 Todd D Prickett,1 Jon Salazar,1 Maria R Parkhust,1 Paul Robbins  ,1  \nNicholas D Klemen,1 Mei Li Kwong,1 Stephanie L Goff  ,1 Steven A Rosenberg,1 James C Yang  1  \nTo cite: Gustafson AM, Bhasin A, Gasmi B, et al. Correlation between recognition of autologous tumor organoids by tumorinfiltrating lymphocytes from metastatic epithelial cancersand clinical response. Journal for ImmunoTherapy of Cancer 2026;14:e014644 . doi:10 . 1136/ jitc-2025-014644  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-014644](jitc-2025-014644)) .  \nAccepted 13 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Surgery Branch, National Cancer Institute Center for  \nCancer Research, Bethesda, Maryland, USA  \n2Surgery, Yale School of Medicine, New Haven, Connecticut, USA 3Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA  \nCorrespondence to  \nDr James C Yang; [jamesyang@mail.nih.gov](jamesyang@mail.nih.gov)  \nABSTRACT  \nBackground Neoantigen-specific tumor-infiltrating lymphocytes (TILs) have the ability to mediate responsesin patients with metastatic epithelial cancers. While some identified factors are associated with response, there is a need for ways to determine which patients will benefit from adoptive cell therapy with TIL. Patient-derived tumor organoids (PDTO) retain the genetic makeup of the tumor from which they are derived, and are a useful tool in personalized medicine to test the effectiveness of anticancer therapies.  \nMethods Tumor organoids were grown from patients with metastatic epithelial cancers treated on a TIL protocol.  \nTIL recognition of autologous PDTO by enzyme-linked immunosorbent spot assays and 4–1BB upregulation, as well as objective Response Evaluation Criteria in Solid Tumors (RECIST) responses to treatment, were measured in a cohort of treated patients. The most common histologies were colorectal (20 patients, 67%), pancreatic (4 patients, 13%), and breast (2 patients, 7%) cancer. Results Recognition of PDTO was driven by major histocompatibility complex (MHC) class I-restricted reactivity and upregulation of MHC in response to interferon-γ was not associated with response. There were no responders in the 9 patients who lacked PDTO recognition on their initial TIL screening compared with seven responses in 18 patients with initial reactivity (p=0 .059) . After TIL were selected and expanded for administration, 15 infusion products showed organoid recognition, with 8 of these patients achieving objective responses (53%), while only 1 of 15 patients without organoid recognition responded (7%; p=0 .014) . Conclusions TIL reactivity against autologous tumor organoid appears to be associated with objective clinical response in patients with metastatic epithelial cancers.  \nBACKGROUND  \nAdoptive cell transfer of tumor-infiltrating lymphocytes (TIL) has the ability to shrink tumors in selected patients with common epithelial cancers.1–3 While treatment  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Human tumor-associated rejection antigens largely derive from the products of tumor-specific mutations and are highly personalized. Tumor-infiltrating lymphocytes from common epithelial cancers, selected for neoantigen reactivity, can cause objective responses when adoptively transferred. Patientderived tumor organoids (PDTO) can be grown from epithelial cancers and retain the genetic features of their tum","cbCaijFN20Hv1WD2","https://ap.wps.com/l/cbCaijFN20Hv1WD2","pdf",8209138,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What was the study aiming to predict for TIL adoptive cell therapy?\",\"answer\":\"The study aimed to determine which patients with metastatic epithelial cancers would benefit from adoptive cell therapy with TIL by assessing recognition of autologous tumor organoids.\"},{\"question\":\"How were tumor organoids (PDTO) and TIL recognition measured?\",\"answer\":\"Tumor organoids were grown from patients on a TIL protocol. TIL recognition of autologous PDTO was measured using enzyme-linked immunosorbent spot assays and 4-1BB upregulation, alongside RECIST objective response assessment.\"},{\"question\":\"Did lack of initial PDTO recognition relate to clinical response?\",\"answer\":\"Yes. There were no responders among 9 patients who lacked PDTO recognition on initial TIL screening, compared with 7 responses in 18 patients with initial reactivity.\"},{\"question\":\"What did the study conclude about autologous tumor organoid recognition?\",\"answer\":\"TIL reactivity against autologous tumor organoids was associated with higher likelihood of objective clinical response in patients with metastatic epithelial cancers.\"}]","Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response | PDF",1790081828,35,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2169e55aef88a6eacc39e341b28c2ff7.webp",983,1310,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f06057b52ce4ee2c999ea49613b7e8d.webp",982,1309,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcac47ca0e4110a843fd2e7f29f2be54.webp",981,1308,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a9b402250af83ac37e21d82b45a9696.webp",980,1306]